Pfizer Reports Phase 3 subgroup analysis Data for Infigratinib in Huntington's disease

Pfizer today announced Phase 3 subgroup analysis results for Infigratinib in patients with Huntington's disease. The study demonstrated that Infigratinib achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Huntington's disease and support the continued development of Infigratinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Infigratinib was consistent with previous observations, with no new safety signals identified.